Australian court affirms Mylan patent invalidation
06-07-2020
Mylan scores multiple sclerosis patent win over Biogen
23-06-2020
ricochet64 / Shutterstock.com
Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera (dimethyl fumarate) yesterday, August 19.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Mylan, Biogen, Tecfidera, patent, dimethyl fumarate, multiple sclerosis, MS, generics, FDA
